Taken together, evidence in support of a liver-specific mechanism of metformin action includes clinical data showing pronounced inhibition of HGP in patients with T2D given metformin in the absence of major changes in peripheral glucose disposal (as discussed below) and/or insulin secretion. Here, INS is linked to type 2 diabetes mellitus.